Kamada

Yahoo Finance • 14 days ago

Kamada Ltd. Q1 2026 Earnings Call Summary

Kamada Ltd. Q1 2026 Earnings Call Summary - Moby Strategic Growth Pillars and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pi... Full story

Yahoo Finance • 14 days ago

Kamada Q1 Earnings Call Highlights

Kamada logo Key Points Interested in Kamada Ltd.? Here are five stocks we like better. Kamada reaffirmed its full-year 2026 outlook for revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, saying fir... Full story

Yahoo Finance • 14 days ago

Kamada Q1 2026 Earnings Call: Complete Transcript

On Wednesday, Kamada (NASDAQ:KMDA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visi... Full story

Yahoo Finance • 15 days ago

Kamada Q1 2026 Earnings Preview

* Kamada (KMDA [https://seekingalpha.com/symbol/KMDA]) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. * The consensus EPS Estimate is $0.12 [https://seekingalpha.com/symbol/KMDA/earnings/estima... Full story

Yahoo Finance • 2 months ago

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

SanAntonioCenter Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasmaand an Estimated Annual Revenue Contribution of $8 Million to $10... Full story

Yahoo Finance • 2 months ago

Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat

The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in... Full story

Yahoo Finance • 3 months ago

Kamada declares $0.25 cash dividend

* Kamada (KMDA [https://seekingalpha.com/symbol/KMDA]) declares $0.25/share cash dividend [https://seekingalpha.com/pr/20432588-kamada-declares-cash-dividend-of-0_25-per-share-to-be-paid-in-accordance-with-an-adopted]. * Payable April... Full story

Yahoo Finance • 7 months ago

Kamada GAAP EPS of $0.09 in-line, revenue of $47M misses by $0.22M; reaffirms FY outlook

* Kamada press release [https://seekingalpha.com/pr/20300078-kamada-reports-strong-third-quarter-and-nine-month-2025-financial-results-with-over-30] (KMDA [https://seekingalpha.com/symbol/KMDA]): Q3 GAAP EPS of $0.09 in-line. * Revenue... Full story

Yahoo Finance • 7 months ago

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine MonthRevenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year... Full story

Yahoo Finance • 7 months ago

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious cond... Full story

Yahoo Finance • 8 months ago

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva, sem bæði innihalda virka e... Full story

Yahoo Finance • 8 months ago

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech

REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“), samstarfsaðila Alvotech í Japan, leyfi til markaðss... Full story

Yahoo Finance • 9 months ago

Alvotech tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley í New York

Alvotech (NASDAQ: ALVO) tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley, sem haldin verður dagana 8.-10. september nk., í New York. Fundir með fjárfestum verða haldnir þriðjudaginn 9. september og Balaji Pra... Full story

Yahoo Finance • 9 months ago

KAMADA LTD (NASDAQ:KMDA) Reports Mixed Q2 2025 Earnings with Strong EPS Beat and Raised Profitability Guidance

KAMADA LTD (NASDAQ:KMDA [https://www.chartmill.com/stock/quote/KMDA/profile]) reported its second-quarter 2025 earnings, delivering mixed results relative to analyst expectations. While revenue slightly missed estimates, earnings per share... Full story

Yahoo Finance • 9 months ago

Vitiligo Treatment Strategic Market Research Report 2025-2030 | Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Vitiligo Treatment was estimated at US$1.5 Billion in 20... Full story

Yahoo Finance • 10 months ago

Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. kl. 12 á hádegi

REYKJAVÍK (6. ágúst 2025) Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. ágúst nk. Fundur til kynningar á uppgjörinu verður sendur út í b... Full story

Yahoo Finance • 10 months ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious con... Full story

Yahoo Finance • 11 months ago

Kamada confirms continuous business operations despite recent events in Middle East

* Kamada (NASDAQ:KMDA [https://seekingalpha.com/symbol/KMDA]) Tuesday said [https://seekingalpha.com/pr/20138521-kamada-confirms-continuous-global-business-operations-and-products-availability-despite]that while circumstances in the Midd... Full story

Yahoo Finance • 3 years ago

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Ye... Full story

Yahoo Finance • 3 years ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions... Full story